Lipella Pharmaceuticals Inc. Common Stock Cash Flow-to-Debt Ratio
Lipella Pharmaceuticals Inc. Common Stock cash flow-to-debt ratio. Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a Cash Flow-to-Debt Ratio of -2734.54x as of September 2025, meaning its operating cash flow of $-2.36 Billion could theoretically repay -2735% of its total liabilities ($862.22K) in one year. See LIPO free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
Cash flow-to-debt ratio of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. Historical debt coverage capacity for Lipella Pharmaceuticals Inc. Common Stock across 6 annual periods. See Lipella Pharmaceuticals Inc. Common Stoc balance sheet independence to measure how much of total assets are equity-financed.
Lipella Pharmaceuticals Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2019–2024)
Lipella Pharmaceuticals Inc. Common Stock cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Lipella Pharmaceuticals Inc. Common Stock. For the full cash flow conversion analysis, see cash flow conversion of Lipella Pharmaceuticals Inc. Common Stoc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.24x | $-3.95 Million | $754.42K | ▲ +28.1% |
| 2023 | -7.28x | $-3.15 Million | $432.73K | ▼ -406.7% |
| 2022 | -1.44x | $-1.83 Million | $1.27 Million | ▲ +14.4% |
| 2021 | -1.68x | $-989.27K | $589.34K | ▼ -2788.3% |
| 2020 | -0.06x | $-28.58K | $491.70K | ▲ +64.7% |
| 2019 | -0.16x | $-39.12K | $237.26K | — |